AVTE vs. VYGR, LFVN, ITOS, AQST, IMMP, NGNE, OLMA, ATYR, RZLT, and AVIR
Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Immutep (IMMP), Neurogene (NGNE), Olema Pharmaceuticals (OLMA), Atyr PHARMA (ATYR), Rezolute (RZLT), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.
Aerovate Therapeutics vs.
Voyager Therapeutics (NASDAQ:VYGR) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.
Voyager Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Voyager Therapeutics presently has a consensus price target of $15.97, indicating a potential upside of 214.92%. Aerovate Therapeutics has a consensus price target of $2.25, indicating a potential downside of 12.79%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Aerovate Therapeutics.
48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Voyager Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 10 mentions for Voyager Therapeutics and 8 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.71 beat Voyager Therapeutics' score of 0.67 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.
Voyager Therapeutics has a net margin of 15.80% compared to Aerovate Therapeutics' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Aerovate Therapeutics' return on equity.
Voyager Therapeutics received 374 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 67.64% of users gave Voyager Therapeutics an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote.
Voyager Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Voyager Therapeutics beats Aerovate Therapeutics on 15 of the 18 factors compared between the two stocks.
Get Aerovate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aerovate Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AVTE) was last updated on 1/20/2025 by MarketBeat.com Staff
